Activity of the keggin polyoxotungstate pm-19 against herpes simplex virus type 2 infection in immunosuppressed mice: Role of peritoneal macrophage activation
✍ Scribed by Dr. Satoru Ikeda; Shigeki Nishiya; Akihiro Yamamoto; Toshihiro Yamase; Chiaki Nishimura; Erik De Clercq
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 521 KB
- Volume
- 41
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The in vivo antiviral activity of the Keggin polyoxotungstate PM‐19 [K~7~(PTi~2~W~10~O~40~) · 6H~2~O] against herpes simplex virus type 2 (HSV‐2) was investigated in mice immunosuppressed by cyclophosphamide (CY). When PM‐19 was administered intraperitoneally to immunosuppressed mice for 3 days (once daily) starting at the time of infection, it prevented death due to HSV‐2 encephalitis in a dose‐dependent manner (10–25 mg/kg). The in vivo anti‐HSV‐2 activity of PM‐19 was superior to that of acyclovir. Intraperitoneal administration of PM‐19 to the immunosuppressed mice significantly increased the number of peritoneal cells, especially macrophages. PM‐19 did not stimulate interferon‐inducing activity or natural killer cell activity, but markedly enhanced peritoneal macrophage functions: (1) phagocytic activity as assessed by measuring the amount of^51^Cr‐labeled sheep red blood cells taken into the macrophages, and (2) extrinsic antiviral activity as monitored by reduction in the numbers of plaque formed upon cocultivation of HSV‐2‐infected HEL cells with the macrophages. These results point to the role of peritoneal macrophage activation in the activity of PM‐19 against HSV‐2 infection in immunosuppressed mice.